Test Price
1,400 AEDโ Home Collection Available
๐ Results in 24โ72 hours
RARA/PML Quantitative Test in UAE | 1,400 AED | DHA Licensed
Executive Summary & Core Metrics
โ Clinical Precision: 99.9% diagnostic sensitivity through RTโqPCR amplification of the PML-RARA fusion transcript, processed under ISO 9001:2015 accreditation (cert. INT/EGQ/2509DA/3139).
โ Specimen Protocol: Hospital extraction only โ conducted strictly within an accredited facility. Bone marrow aspiration or peripheral blood draw by licensed hematology staff with cold-chain courier transfer to DNA Labs UAE.
โ Consultation: Post-result telephonic interpretation by a DHA-licensed Consultant Medical Genetics specialist.
โ Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The RARA/PML Quantitative Test is a highly sensitive molecular assay that detects the PML-RARA fusion gene, the definitive marker for acute promyelocytic leukemia (APL). This quantitative RTโPCR assay measures the level of fusion transcript, essential for diagnosis, risk stratification, and minimal residual disease (MRD) monitoring.
| Feature | Our Test (RTโqPCR) | FISH (Qualitative) | Karyotyping |
|---|---|---|---|
| Method | Quantitative Reverse Transcription PCR | Fluorescence In Situ Hybridization | Chromosomal Banding Analysis |
| Sensitivity | >99% (1 leukemic cell in 105) | ~90% (requires โฅ2% abnormal nuclei) | ~70โ80% (only dividing cells) |
| Turnaround Time | 24โ72 hours | 2โ4 days | 7โ14 days |
| MRD Monitoring | Yes โ quantitative | No | No |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403), advises: โThe PML-RARA quantitative assay is the molecular gold standard for confirming acute promyelocytic leukemia and tracking therapeutic response. A detectable transcript level guides urgent clinical decisions, while sustained negativity allows for treatment de-escalation. Treatment must never be interrupted without explicit hematology oversight.โ
Advisory & Safety Protocols
Critical Medication Warning
Do not discontinue any prescribed medication (including allโtrans retinoic acid, arsenic trioxide, or anticoagulants) without consulting your doctor.
Exclusion Criteria & Emergency Red Flags
- Not for routine screening โ only for confirmed or highly suspected acute promyelocytic leukemia (APL) after haematologist referral.
- Minors require parental consent or legal guardian approval.
- If you experience sudden bleeding, persistent fever, severe fatigue, or confusion, seek emergency care immediately โ do not wait for test results.
Patient FAQ & Clinical Guidance
1. What is the RARA/PML Quantitative Test and how does it work?
This advanced molecular assay quantifies the PML-RARA fusion gene to confirm a diagnosis of acute promyelocytic leukemia and to monitor minimal residual disease with 99.9% sensitivity. The test uses a bone marrow aspirate or peripheral blood sample to measure fusion transcript copy numbers through reverse transcription quantitative PCR (RTโqPCR). It is the gold standard for identifying APL and tracking treatment response, often enabling clinicians to adjust therapy as soon as molecular remission is achieved.
2. What are the clinical implications of a positive result?
A detectable PML-RARA transcript confirms the diagnosis of acute promyelocytic leukemia and requires urgent initiation of targeted therapy. Serial quantitative monitoring guides treatment duration and confirms molecular remission. Sustained negativity over time supports treatment de-escalation or discontinuation under strict hematological surveillance. All results must be interpreted in conjunction with clinical presentation and blood counts.
3. How is the sample collected and what preparations are required?
Sample collection is performed exclusively within an accredited hospital setting by a licensed hematologist or trained phlebotomist. An initial blood draw is standard; a bone marrow aspiration may be required for baseline diagnosis. Please bring your complete clinical history, including any prior leukemia treatment records. Our team adheres to strict cold-chain protocols to preserve RNA integrity. Results are interpreted by a DHA-licensed Consultant Medical Genetics specialist and communicated securely with you.
UAE Regulatory & Data Privacy Adherence
Trust & Compliance Framework
DNA Labs UAE operates under DHA Facility License No. 1143. All genetic and molecular data are processed in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols adhere strictly to Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | RARA/PML Quantitative Test |
| Price (AED) | 1,400 |
| Turnaround Time | 24โ72 hours |
| Sample Type / Matrix | Hospital Extraction Only โ Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. |
| Methodology Used | Reverse Transcription Quantitative PCR (RTโqPCR) |
| ICD-10-CM Code | C92.4 |
| LOINC Code | 60420-8 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
Preparation Required
["Bring complete clinical history", "Provide prior leukemia treatment records"]
Medically Reviewed by Dr. Lina Osama Zaki Quteineh
All content reviewed by qualified professionals for accuracy.
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians